These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 36461705)
21. The eliminate hepatitis C (EC) experience study: baseline characteristics of a cohort of people who inject drugs in Melbourne, Australia. Gunn J; O'Keefe D; Draper BL; Djordjevic F; Ryan K; Kerr P; Elsum I; Gold J; Layton C; Chan K; Dietze P; Higgs P; Doyle J; Stoové MA; Hellard M; Pedrana A BMJ Open; 2023 Jul; 13(7):e071665. PubMed ID: 37400235 [TBL] [Abstract][Full Text] [Related]
22. A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study. Conway A; Valerio H; Alavi M; Silk D; Treloar C; Hajarizadeh B; Marshall AD; Martinello M; Milat A; Dunlop A; Murray C; Prain B; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Christmass M; Wade A; Montebello M; Dore GJ; Grebely J; Viruses; 2022 Jul; 14(7):. PubMed ID: 35891535 [TBL] [Abstract][Full Text] [Related]
23. Associations of criminal justice and substance use treatment involvement with HIV/HCV testing and the HIV treatment cascade among people who use drugs in Oakland, California. Lambdin BH; Kral AH; Comfort M; Lopez AM; Lorvick J Addict Sci Clin Pract; 2017 Jun; 12(1):13. PubMed ID: 28610602 [TBL] [Abstract][Full Text] [Related]
24. Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India. Patel EU; Solomon SS; Mcfall AM; Srikrishnan AK; Pradeep A; Nandagopal P; Laeyendecker O; Tobian AAR; Thomas DL; Sulkowski MS; Kumar MS; Mehta SH Int J Drug Policy; 2018 Jul; 57():51-60. PubMed ID: 29679811 [TBL] [Abstract][Full Text] [Related]
25. Interventions to increase linkage to care and adherence to treatment for hepatitis C among people who inject drugs: A systematic review and practical considerations from an expert panel consultation. Schwarz T; Horváth I; Fenz L; Schmutterer I; Rosian-Schikuta I; Mårdh O Int J Drug Policy; 2022 Apr; 102():103588. PubMed ID: 35101667 [TBL] [Abstract][Full Text] [Related]
26. Hepatitis C Testing, Status and Treatment among Marginalized People Who Use Drugs in an Inner City Setting: An Observational Cohort Study. Boucher LM; Bayoumi AM; Mark AE; Cooper C; Martin A; Marshall Z; Boyd R; Oickle P; Diliso N; Pineau D; Renaud B; LeBlanc S; Tyndall M; Lee OM; Kendall CE Subst Use Misuse; 2019; 54(1):18-30. PubMed ID: 29932800 [TBL] [Abstract][Full Text] [Related]
27. Efficacy of assisted partner services for people who inject drugs in Kenya to identify partners living with HIV and hepatitis C virus infection: a prospective cohort study. Monroe-Wise A; Mbogo L; Sambai B; Ludwig-Barron N; Guthrie BL; Bukusi D; Chohan BH; Masyuko S; Scott J; Juma E; Macharia P; Kingston H; Sinkele W; Gitau E; Bosire R; Musyoki H; Herbeck J; Farquhar C Lancet Glob Health; 2024 May; 12(5):e859-e867. PubMed ID: 38614633 [TBL] [Abstract][Full Text] [Related]
28. Point-of-care Hepatitis C virus testing and linkage to treatment in an Australian inner-city emergency department. Hutton J; Doyle J; Zordan R; Weiland T; Cocco A; Howell J; Iser S; Snell J; Fry S; New K; Sloane R; Jarman M; Phan D; Tran S; Pedrana A; Williams B; Johnson J; Glasgow S; Thompson A Int J Drug Policy; 2019 Oct; 72():84-90. PubMed ID: 31351752 [TBL] [Abstract][Full Text] [Related]
29. Hepatitis C antibody prevalence and behavioral correlates in people who inject drugs attending harm reduction services in Lisbon, Portugal. Curado A; Nogueira PJ; Virgolino A; Santa Maria J; Mendão L; Furtado C; Antunes F Front Public Health; 2022; 10():952909. PubMed ID: 36081480 [TBL] [Abstract][Full Text] [Related]
30. Service utilization patterns and characteristics among clients of integrated supervised consumption sites in Toronto, Canada. Nassau T; Kolla G; Mason K; Hopkins S; Tookey P; McLean E; Werb D; Scheim A Harm Reduct J; 2022 Mar; 19(1):33. PubMed ID: 35351160 [TBL] [Abstract][Full Text] [Related]
31. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy. Iversen J; Dore GJ; Starr M; Catlett B; Cunningham P; Geddes L; Maher L Int J Drug Policy; 2020 Sep; 83():102837. PubMed ID: 32645585 [TBL] [Abstract][Full Text] [Related]
32. Need for integration of hepatitis C (HCV) services in community-based settings for people who inject drugs: results from a global values and preferences survey. Di Ciaccio M; Villes V; Perfect C; El Kaim JL; Donatelli M; James C; Easterbrook P; Delabre RM Harm Reduct J; 2023 Feb; 20(1):15. PubMed ID: 36759855 [TBL] [Abstract][Full Text] [Related]
33. Utility of a one-step screening and diagnosis strategy for viremic HCV infection among people who inject drugs in Catalonia. Saludes V; Antuori A; Folch C; González N; Ibáñez N; Majó X; Colom J; Matas L; Casabona J; Martró E; Int J Drug Policy; 2019 Dec; 74():236-245. PubMed ID: 31706159 [TBL] [Abstract][Full Text] [Related]
34. Rapid hepatitis C virus point-of-care RNA testing and treatment at an integrated supervised consumption service in Toronto, Canada: a prospective, observational cohort study. Lettner B; Mason K; Greenwald ZR; Broad J; Mandel E; Feld JJ; Powis J Lancet Reg Health Am; 2023 Jun; 22():100490. PubMed ID: 37388709 [TBL] [Abstract][Full Text] [Related]
35. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study. Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J; Int J Drug Policy; 2022 Jul; 105():103706. PubMed ID: 35533635 [TBL] [Abstract][Full Text] [Related]
36. Hepatitis C among vulnerable populations: A seroprevalence study of homeless, people who inject drugs and prisoners in London. Aisyah DN; Shallcross L; Hayward A; Aldridge RW; Hemming S; Yates S; Ferenando G; Possas L; Garber E; Watson JM; Geretti AM; McHugh TD; Lipman M; Story A J Viral Hepat; 2018 Nov; 25(11):1260-1269. PubMed ID: 29851232 [TBL] [Abstract][Full Text] [Related]
37. Mapping the hepatitis C cascade of care in people attending drug treatment services in England: A data linkage study. Ireland G; Simmons R; Hickman M; Eastwood B; Ramsay M; Mandal S Int J Drug Policy; 2019 Oct; 72():55-60. PubMed ID: 31257040 [TBL] [Abstract][Full Text] [Related]
38. Factors associated with hepatitis C testing, treatment, and current hepatitis C infection among men and women who inject drugs: The ETHOS engage study. Valerio H; Marshall AD; Conway A; Treloar C; Carter L; Martinello M; Henderson C; Amin J; Read P; Silk D; Degenhardt L; Prain B; Alavi M; Dore GJ; Grebely J; Int J Drug Policy; 2024 May; 127():104394. PubMed ID: 38608357 [TBL] [Abstract][Full Text] [Related]
39. Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis. Karimi SE; Bayani A; Higgs P; Bayat AH; Hemmat M; Ahounbar E; Armoon B; Fakhri Y Subst Abuse Treat Prev Policy; 2020 Aug; 15(1):64. PubMed ID: 32831107 [TBL] [Abstract][Full Text] [Related]
40. The impact of point-of-care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study. Howell J; Traeger MW; Williams B; Layton C; Doyle JS; Latham N; Draper B; Bramwell F; Membrey D; McPherson M; Roney J; Stoové M; Thompson AJ; Hellard ME; Pedrana A J Viral Hepat; 2022 May; 29(5):375-384. PubMed ID: 35274403 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]